Fully Human Tumor-based Matrix in Three-dimensional Spheroid Invasion Assay
May 7th, 2019
17.4K views
Tumor microenvironment is an essential part of cancer growth and invasion. To mimic carcinoma progression, a biologically relevant human matrix is needed. This protocol introduces an improvement for the in vitro three-dimensional spheroid invasion assay by applying a human leiomyoma-based matrix. The protocol also introduces a computer-based cell invasion analysis.
Overview
This study presents a novel in vitro three-dimensional spheroid invasion assay utilizing a human leiomyoma-derived matrix, enhancing the mimicry of carcinoma progression. The method allows for improved analysis of tumor cell invasion and is applicable to patient-derived solid cancer samples.
Key Study Components
Area of Science
- Cancer Biology
- Tumor Microenvironment
- In Vitro Assays
Background
- The tumor microenvironment plays a critical role in cancer growth and invasion.
- A biologically relevant human tumor matrix is essential for accurate modeling of carcinoma progression.
- This method is less temperature sensitive compared to classical spheroid assays.
- It is suitable for personalized medicine applications, including chemoradiation therapies.
Purpose of Study
- To develop a human tumor matrix-based assay for studying cancer cell invasion.
- To provide a protocol that minimizes technical challenges associated with traditional methods.
- To enable high-throughput drug testing and live-cell analysis.
Methods Used
- Generation of multicellular tumor spheroids in ultra-low attachment plates.
- Preparation of a human myoma-derived matrix and fibrinogen for the invasion assay.
- Daily imaging of spheroid invasion using an inverted microscope.
- Image analysis using ilastik for segmentation and area quantification.
Main Results
- Cells in the human myoma-derived matrix invaded rapidly, demonstrating effective modeling of tumor behavior.
- Comparison with other matrices showed distinct invasion patterns, highlighting the advantages of the human-derived matrix.
- Live-cell analysis revealed dynamic cell movement and invasion over time.
- The method can be adapted to study the effects of various treatments on tumor invasion.
Conclusions
- The human myoma-derived matrix provides a robust platform for studying cancer cell invasion.
- This assay can facilitate research into therapeutic interventions for cancer.
- Proper handling and methodology are crucial for successful implementation of the assay.
Frequently Asked Questions
What is the significance of the tumor microenvironment in cancer?
The tumor microenvironment influences cancer growth, invasion, and response to therapies.
How does this method differ from traditional spheroid assays?
This method is less temperature sensitive and does not require spheroid transfer, making it easier to use.
What types of cancer samples can be used with this assay?
The assay is suitable for patient-derived solid cancer samples, including head and neck carcinoma.
What are the main applications of this assay?
Applications include high-throughput drug testing, live-cell analysis, and studying the effects of treatments on invasion.
What precautions should be taken when handling the matrix?
Careful handling is essential, especially during the addition of fibrinogen, to prevent disruption of spheroid positioning.
How can image analysis be performed?
Image analysis can be conducted using ilastik for segmentation and area quantification of the invasion.
Executive Industry Relevance
This assay addresses a critical gap in preclinical cancer research by providing a human tumor-derived matrix that better recapitulates the in vivo microenvironment compared to animal-derived alternatives. It enables more predictive modeling of carcinoma invasion, supporting target validation and mechanistic de-risking in early discovery. The platform is suitable for screening applications and translational continuity, particularly for head and neck carcinoma and patient-derived samples.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses by enabling functional validation of targets in a human-relevant extracellular matrix context.
- Operational Value: Reduces mechanistic ambiguity through direct observation of invasion phenotypes in a biologically pertinent system.
- Predictive Value: Supports portfolio triage by identifying compounds that modulate invasion in a model predictive of human tumor behavior.
Screening & Assay Development
- Scientific Value: Provides a standardized, reproducible 3D system for quantitative assessment of compound effects on cell invasion.
- Operational Value: Enables high-throughput drug testing with minimal technical variability due to reduced temperature sensitivity and no spheroid transfer requirement.
- Scalability: Compatible with 96-well ultra-low attachment plates, supporting assay miniaturization and multi-condition screening.
Translational & Preclinical Research
- Translational Continuity: Uses human leiomyoma-derived matrix to bridge discovery findings with preclinical validation in a disease-relevant system.
- Biomarker Alignment: Facilitates live-cell analysis of invasion dynamics, enabling correlation with molecular signatures or treatment responses.
- Risk-Adjusted Advancement: Supports go/no-go decisions by quantifying invasion inhibition, a key phenotypic endpoint in metastasis prevention.
Pipeline & Workflow Integration
The assay fits within the discovery continuum from target validation through lead identification to preclinical efficacy testing, particularly for metastasis-focused programs.
- Discovery Biology: Supports hypothesis testing of invasion drivers and pathway modifiers in a human tumor microenvironment context.
- Screening: Delivers quantitative, imaging-based readouts suitable for automated analysis and compound profiling.
- Analytics: Generates invasion area measurements via ilastik and ImageJ, enabling statistical comparison across conditions.
- Translational Research: Connects to preclinical work by modeling a key step in metastasis using a human-derived matrix.
- Enterprise Reuse: Establishes a reusable platform applicable across solid cancer types and therapeutic modalities, including chemoradiation.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence in target validation by reducing reliance on non-human matrices that poorly mimic human tumor stroma.
- Operational Value: Improves reproducibility and standardization through a defined matrix preparation protocol and imaging workflow.
- Strategic Value: Increases capital efficiency by improving early prediction of clinical translatability, reducing late-stage failure due to poor metastasis modeling.
- Portfolio Impact: Enables risk-adjusted prioritization of leads based on invasion inhibition potency in a human-relevant system.
Implementation Considerations
- Requires expertise in 3D cell culture, matrix handling, and sterile technique for fibrin gel preparation.
- Dependent on access to inverted microscopes, ilastik, and Fiji ImageJ for imaging and analysis.
- Necessitates cross-team standardization of spheroid formation and matrix dispensing to avoid positional artifacts.
- Adaptation to other model systems requires validation of matrix compatibility and invasion kinetics.
- Practical limitation: Fibrinogen initiates rapid gelation, demanding precise, timed pipetting to maintain spheroid integrity.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in this assay?
Null hypothesis testing determines whether observed invasion differences between conditions are statistically significant, supporting confident target modulation claims. It enables rigorous comparison of control versus treatment groups in invasion area measurements. This statistical foundation is essential for de-risking targets before advancing to preclinical studies.
How does independent variable isolation fit the discovery pipeline?
Isolating independent variables such as matrix composition or drug treatment allows clear attribution of phenotypic changes to specific factors. In this assay, comparing invasion in HMDM/fibrin versus MSDM or collagen isolates the effect of the human tumor matrix. This approach supports mechanistic de-risking by clarifying which variables drive invasion phenotypes.
What quantitative dependent variable measurements enable decision-making?
The assay quantifies invasion area over time using ilastik segmentation and ImageJ analysis, providing a continuous, objective readout of cellular invasion. These measurements enable dose-response modeling and IC50 estimation for invasion-inhibiting compounds. Quantitative outputs support go/no-go decisions in lead optimization based on phenotypic potency.
Why do replication requirements matter for cross-functional collaboration?
Replication ensures that invasion phenotypes are consistent across experiments, operators, and laboratories, building confidence in assay reliability. Standardized spheroid formation and matrix preparation reduce variability, enabling comparable results between discovery and translational teams. This consistency is vital for aligning hit validation, lead optimization, and preclinical groups on shared data.
What statistical analysis capabilities are required before implementation?
Implementation requires the ability to perform group comparisons using t-tests or ANOVA on invasion area data from multiple replicates. Software such as GraphPad Prism or R is typically used to assess statistical significance and effect size. These capabilities ensure that observed differences are robust and not due to random variation, supporting data-driven advancement decisions.
